Nasal versus bronchial and nasal response to oral aspirin challenge : clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis

2003
journal article
article
35
cris.lastimport.scopus2024-04-07T16:44:08Z
dc.abstract.enBackground: Aspirin-induced asthma/rhinitis (AIAR) is characterized by the altered metabolism of leukotrienes and proinflammatory prostaglandins. The basal and postchallenge levels of eicosanoids might reflect the clinical and biochemical characteristics of patients with distinct types of hypersensitive responses to aspirin. Objective: We compared clinical and eicosanoid profiles of patients with AIAR showing both bronchial and nasal versus isolated nasal responses to aspirin challenge. Methods: Twenty-three patients with AIAR underwent the single-blind, oral, placebo-controlled aspirin challenge. The bronchial response (BR) was evidenced by dyspnea and spirometry, whereas the nasal response (NR) was evidenced by nasal symptoms and acoustic rhinometry and/or rhinomanometry. Urinary leukotriene E4 (uLTE4), serum and urinary stable prostaglandin D2 metabolite, and 9α,11β-prostaglandin F2 (9α,11β-PGF2), were determined at baseline and after the aspirin challenge. Results: Fifteen subjects showed BR and NR (BNR), whereas 8 showed NR only. Basal uLTE4 in the BNR group was significantly higher than in the NR group. After aspirin challenge, it increased significantly in both groups. Serum 9α,11β-PGF2 increased after aspirin challenge in the BNR group only. The patients with BNR had more severe AIAR. Conclusions: BNR to aspirin in AIAR indicates a more advanced disease and more profound underlying eicosanoid metabolism disturbances.pl
dc.affiliationWydział Lekarskipl
dc.contributor.authorŚwierczyńska-Krępa, Monika - 133642 pl
dc.contributor.authorNiżankowska-Mogilnicka, Ewa - 132989 pl
dc.contributor.authorZarychta, Jacek - 133893 pl
dc.contributor.authorGielicz, Anna - 129493 pl
dc.contributor.authorSzczeklik, Andrzej - 133558 pl
dc.date.accessioned2020-06-03T07:49:11Z
dc.date.available2020-06-03T07:49:11Z
dc.date.issued2003pl
dc.date.openaccess0
dc.description.accesstimew momencie opublikowania
dc.description.number5pl
dc.description.physical995-1001pl
dc.description.versionostateczna wersja wydawcy
dc.description.volume112pl
dc.identifier.doi10.1016/S0091-6749(03)02015-3pl
dc.identifier.eissn1097-6825pl
dc.identifier.issn0091-6749pl
dc.identifier.projectROD UJ / OPpl
dc.identifier.urihttps://ruj.uj.edu.pl/xmlui/handle/item/156928
dc.languageengpl
dc.language.containerengpl
dc.rightsUdzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa*
dc.rights.licenceCC-BY-NC-ND
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/legalcode.pl*
dc.share.typeinne
dc.subject.enaspirin-induced asthma/rhinitispl
dc.subject.enaspirin challengepl
dc.subject.enleukotriene E_{4}pl
dc.subject.enprostaglandin D_{2}pl
dc.subject.en9\alpha,11\beta -prostaglandin F_{2}pl
dc.subtypeArticlepl
dc.titleNasal versus bronchial and nasal response to oral aspirin challenge : clinical and biochemical differences between patients with aspirin-induced asthma/rhinitispl
dc.title.journalJournal of Allergy and Clinical Immunologypl
dc.typeJournalArticlepl
dspace.entity.typePublication

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
0
Views per month